VolitionRX (VNRX) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
11 Feb, 2026Executive summary
Special Meeting scheduled for March 31, 2026, to vote on two key proposals: issuing shares exceeding 20% of outstanding stock to Lind Global Asset Management XII LLC and authorizing a reverse stock split at a ratio between 1-for-5 and 1-for-20, at the board's discretion.
Board unanimously recommends voting in favor of both proposals.
Record date for voting eligibility is February 9, 2026, with 135,565,326 shares outstanding.
Voting can be done online, by phone, mail, or in person, with results to be announced at the meeting and via SEC filings.
Voting matters and shareholder proposals
Proposal 1: Approve issuance of additional shares exceeding 20% of outstanding stock to Lind Global Asset Management XII LLC, in compliance with NYSE American Rule 713.
Proposal 2: Approve amendment to authorize a reverse stock split at a ratio between 1-for-5 and 1-for-20, at the board's discretion.
Both proposals require a majority vote of shares present or represented by proxy.
Abstentions count as votes against; broker non-votes have no effect.
Board of directors and corporate governance
Board of directors has full discretion to implement or abandon the reverse stock split even if approved by shareholders.
No director or executive officer has a substantial interest in the reverse stock split not shared by all shareholders.
Latest events from VolitionRX
- Asset-light, licensing-driven growth targets multi-billion dollar diagnostics markets with strong IP.VNRX
Corporate presentation - First half 2026 revenue up 112% with major clinical, licensing, and cost reduction progress.VNRX
Q2 2026 - Platform-agnostic diagnostics and licensing drive growth in cancer, sepsis, and animal health.VNRX
Corporate presentation - 3.3 million shares registered for resale by a noteholder, with no proceeds to the company.VNRX
Registration filing - Nu.Q blood tests enable rapid, cost-effective cancer detection and monitoring worldwide.VNRX
Study update - Shareholders will vote on directors, auditor, compensation, share reduction, and a new incentive plan.VNRX
Proxy filing - Major licensing deals, global launches, and clinical milestones drive growth in cancer and sepsis diagnostics.VNRX
Corporate presentation - Q1 2026 revenue reached $1.0M, but net loss increased amid clinical and licensing progress.VNRX
Q1 2026 - Board recommends approval of all proposals, including share reduction and new incentive plan.VNRX
Proxy filing - Revenue up 40% to $1.7M, with clinical milestones and new funding amid going concern risk.VNRX
Q4 2025